Form 4: Director William Bradley Increases Stake in Fractyl Health

Director William Bradley acquired 68,493 shares of Fractyl Health (GUTS) and received a stock option grant for 22,500 shares.

Summary

• Director William Bradley purchased 68,493 shares of common stock at a price of $0.7348 per share on June 10, 2026.
• Following the purchase, Bradley holds a total of 84,622 shares of common stock.
• Bradley was also granted a stock option for 22,500 shares with an exercise price of $0.7318, expiring on June 9, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as the director's open market purchase indicates personal capital commitment to the company's future.

Positives

• Director demonstrates confidence in the company by increasing his personal equity stake through an open market purchase.

Negatives

• None identified.

Risks

• The stock option grant is subject to continued service on the board of directors through the vesting date.

Future Outlook

The stock options vest on the earlier of the next annual meeting of stockholders or the first anniversary of the grant, contingent upon continued board service.

Industry Context

StockSavvy.ai notes that insider buying, particularly by board members, is often viewed as a positive signal of management's belief in the company's long-term valuation, especially in the biotech/medtech sector where stock prices can be volatile.

Comparison to Industry Standards

• Director equity participation is standard practice for aligning board interests with shareholder value in publicly traded healthcare companies.

Stakeholder Impact

• Shareholders may perceive the director's purchase as a vote of confidence in the company's current valuation.

Next Steps

• Vesting of the 22,500 stock options upon the next annual meeting or the first anniversary of the grant.

Key Dates

Keywords

Fractyl Health, GUTS, Insider Trading, Director Purchase, SEC Form 4